KISSIMMEE, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ECD Automotive Design, the world’s largest Land Rover and Jaguar restoration company known for its bespoke Defenders, Range Rovers, Jaguar E-Types, Ford Mustangs, Toyota FJs, and the ECDXCTC INEOS Grenadier and Defender II, announces Project Wrangler, a Defender 110 Soft Top designed for drivers who value mechanical engagement, open-air freedom, and intentional craftsmanship. Built on the D110 platform, Project Wrangler blends classic Defender character wi ...

文章核心观点 - N2OFF公司通过其合作伙伴Solterra，在德国旗舰太阳能项目的开发上取得关键进展，项目按计划推进并优化了财务条款，从而降低了监管风险、创造了项目价值，并增强了未来的变现灵活性 [1][3][7] 德国项目进展 - 德国旗舰太阳能光伏及储能项目已进入许可审批的最后阶段，预计将于2026年第三季度获得批准 [1][3] - 首次公众咨询阶段接近完成，迄今为止未收到反对意见或重大修改要求，显示出良好的监管一致性、社区认可和规划完整性 [4] - 最终咨询阶段的草案分区计划定于2026年1月下旬假期后提交，保持了清晰的发展时间线 [4] 财务条款优化与价值创造 - Solterra执行了开发协议修正案，将获得约34万美元的预付款以加速进展，同时每兆瓦的开发费用降低了1.1万欧元 [5] - 此项条款重新谈判为项目层面创造了约170万美元的价值，增加了潜在利润 [5][10] - 从资本配置角度看，这笔交易高效地重新部署了有限的短期资本，显著改善了长期项目经济性，增加了隐含股权价值，并提升了未来退出或运营回报 [6] 战略与业务影响 - 德国的最新进展推动了公司欧洲投资组合沿着“准备建设”价值曲线前进 [7] - 通过系统性地降低监管风险、收紧开发经济性并保持变现灵活性，公司继续将自身定位为专注于可扩展、有基础设施支持的价值创造的纪律严明的资本配置者 [7] - 公司增强了变现的灵活性，从2026年下半年开始，拥有多个高可见度的价值实现途径 [10] 公司业务概览 - N2OFF是一家药物发现公司，同时基于“准备建设”商业模式投资太阳能资产 [1] - 公司拥有MitoCareX Bio Ltd 100%的股权，该公司是一家通过线粒体SLC25蛋白家族靶向癌症治疗和其他疾病的药物递送公司 [8] - 公司是欧盟三个国家四个太阳能项目的领投方，这些项目均由Solterra Renewable Energy Ltd引入 [8] - 公司还控制着Save Foods Ltd约98%的股权，这是一家专注于采后处理技术以减少水果蔬菜病原体污染的以色列公司 [8]

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted ...

Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa’s proprietary combination treatment of PCS6422 and capecitabine, in pat ...

Initiation of eAArly DETECT 2 - U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population in Preparation for ReconAAsense U.S. FDA Pivotal Trial Results from Feasibility Study of Biomarker Panel in Pancreatic Cancer ProjectStudy Demonstrated a Sensitivity of 100% and Specificity of 95% BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagn ...

The acquisition, which is subject to closing conditions, would encompass Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction Tel Aviv, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, today announced that it has received the requisite stockholder approval via written consent of the majority of its stockholders (the “Stockholder Consent”) for its previously an ...

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is alerting investors in Primo Brands Corporation (NYSE: PRMB) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 12, 2026.   The firm urges investors who suffered substantial losses to contact our firm now. The lawsuit seeks to recover investor losses sustained after the disclosure of an allegedly concealed severe, operational crisi ...

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 9, 2026. The lawsuit follows a series of regulatory setbacks—including an SEC subpoena and a devastating Complete Response Letter (CRL) from the FDA—that led to a sharp stock decline, with the final news t ...

SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Stride, Inc. (NYSE: LRN) that the deadline to move the Court for appointment as lead plaintiff in the pending securities class action lawsuit is January 12, 2026. The firm urges investors who suffered substantial losses in LRN to contact Hagens Berman now to discuss their rights. The lawsuit seeks to recover investor losses sustained after the purported disclosure of two ...

Raanana, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions today announced positive results from a new in-vitro pre-clinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an accepted and standard comparator used in nasal barrier products. The study, conducted ...